MAMMALIAN TARGET OF RAPAMYCIN AND 3-PHOSPHATIDYLINOSITOL 3-KINASE PATHWAY INHIBITION ENHANCES GROWTH INHIBITION OF TRANSFORMING GROWTH FACTOR-β1 IN PROSTATE CANCER CELLS
- 1 October 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 172 (4), 1333-1337
- https://doi.org/10.1097/01.ju.0000138829.97838.19
Abstract
Serum transforming growth factor (TGF)-beta1 is elevated in patients with metatatic prostate cancer. Although growth inhibitory in normal prostate epithelial cells, cancer cells are often resistant to TGF-beta1. The role of phosphatidylinositol 3-kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling in TGF-beta1 resistance was studied in prostate cancer cell lines. PC3 and LNCaP human prostate cancer cell lines were exposed for 72 hours to rapamycin (mTOR inhibition), LY294002 (PI3K/AKT inhibition) and TGF-beta1 in a proliferation (WST-1) assay. A TGF-beta1 receptor II, stably transfected LNCaP cell line was used (LNCaP-RII). TGF-beta1/SMAD (Sma and MAD [mothers-against-decapentaplegic]homologue) signaling was assessed using the pGL3-SBE4-luc (SBE4) reporter plasmid. Immunoblotting and immunocytochemistry were applied to evaluate phosphorylated Smad and E-cadherin expression in relation to mTOR inhibition and TGF-beta1 exposure. In PC3 and LNCaP-RII cells mTOR and PI3K/AKT inhibition caused TGF-beta1 to become inhibitory for growth. The synergistic effect was associated with the increased expression of phosphorylated Smad and induction of SBE4 reporter plasmid expression. E-cadherin in PC3 cells increased upon mTOR inhibition and TGF-beta1 exposure. Inhibition of growth signaling through PI3K/AKT/mTOR renders prostate cancer cells sensitive to TGF-beta1 induced growth inhibition.Keywords
This publication has 13 references indexed in Scilit:
- Sirolimus: its discovery, biological properties, and mechanism of actionTransplantation Proceedings, 2003
- Biochemical staging of prostate cancerPublished by Elsevier ,2003
- Rapamycin induces Smad activity in prostate cancer cell linesUrological Research, 2003
- Rapamycin Potentiates Transforming Growth Factor β-Induced Growth Arrest in Nontransformed, Oncogene-Transformed, and Human Cancer CellsMolecular and Cellular Biology, 2002
- The development of androgen-independent prostate cancerNature Reviews Cancer, 2001
- An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten+/−miceProceedings of the National Academy of Sciences, 2001
- Role of Transforming Growth Factor β in Human DiseaseNew England Journal of Medicine, 2000
- The L45 loop in type I receptors for TGF‐β family members is a critical determinant in specifying Smad isoform activationFEBS Letters, 1998
- Identification and Functional Characterization of a Smad Binding Element (SBE) in the JunB Promoter That Acts as a Transforming Growth Factor-β, Activin, and Bone Morphogenetic Protein-inducible EnhancerJournal of Biological Chemistry, 1998
- Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomasOncogene, 1997